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Abstract 
Squid gelatin obtained from inner and outer tunics was hydrolyzed with Alcalase to 
isolate antioxidant peptide sequences. The ACE-inhibitory activity of the isolated 
peptides was also evaluated. After fractionation by ultrafiltration and size-exclusion 
chromatography into four fractions, the antioxidant activity of the peptide fractions was 
determined by radical scavenging ability and ferric reducing power. Fraction FIII 
showed the highest antioxidant activity, although slight differences could be expected in 
the antioxidant activity of the different fractions based on the amino acid composition. 
FIII was subjected to liquid chromatography and tandem mass spectrometry (LC-
MS/MS) and two major compounds were identified: the compound with m/z 952.42, 
which could be mostly comprised by the carbohydrate fucose, and the peptide with m/z 
1410.63. Three possible sequences were proposed for this peptide, and the contribution 
of Leu or Hyp residues to the antioxidant and ACE-inhibitory activities of the resulting 
sequence was evaluated. The presence of Leu residues in the peptide sequence in 
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replacement of Hyp seems to play an important role in the antioxidant and ACE-
inhibitory activity. 
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1. Introduction 
Giant squid (Dosidicus gigas) is widely distributed in the Pacific Ocean, and is 
especially abundant near the coasts of Peru and Mexico. The big size of the mantle 
together with the fact that it is usually marketed as cleaned and peeled mantle, imply the 
generation of important amounts of collagenous residues (inner and outer tunics), which 
could yield high value-added products. Squid skin gelatins have been reported to give 
biologically active peptides with high antioxidant activity, due to their radical 
scavenging activities, chelating effects on metal ions, reducing power or lipid 
peroxidation (Mendis, Rajapakse, Byun & Kim, 2005a; Rajapakse, Mendis, Byun & 
Kim, 2005; Lin & Li, 2006; Giménez, Alemán, Montero & Gómez-Guillén, 2009). 
However, to the best of our knowledge, ACE-inhibitory capacity has not been described 
in squid skin gelatin hydrolysates, although this activity has been reported in collagen 
and gelatin hydrolysates from other marine species (Kim, Byun, Park & Shahidi, 2001; 
Fahmi, Morimura, Guo, Shigematsu, Kida & Uemura, 2004; Kim & Mendis, 2006; 
Zhao, Li, Liu, Dong, Zhao & Zen, 2007). 
Lipid oxidation leads to the loose of food quality and shortening of shelf-life, as well as 
the production of potentially toxic reaction products. Furthermore, oxidative damage is 
related to numerous health disorders such as diabetes, cancer, neurodegenerative and 
inflammatory diseases (Pryor, 1982; Butterfield, Castenga, Pocernich, Drake, 
Scapagnini & Calabrese, 2002).  
Hypertension is a worldwide problem of epidemic proportions that affects 15-20% of all 
adults. Angiotensin-I converting enzyme (ACE) plays an important role in the 
regulation of blood pressure and hypertension because catalyzes the conversion of 
inactive angiotensin-I into angiotensin-II, a potent vasoconstrictor (Goodfriend, Elliott 
& Catt, 1996) and inactivates bradykinin, a potent vasodilator (Witherow, Helmy, 
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Webb, Fox & Newby, 2001). Synthetic inhibitors of ACE are often used to treat 
hypertension (Pahor, Psaty, Alderman, Applegate, Williamson & Furberg, 2000) and 
other cardio-related diseases. However, these compounds can cause adverse side effects 
(Atkinson & Robertson, 1979) and, therefore, interest for natural inhibitor has 
increased.  
Biological activities of protein hydrolysates are related to the amino acid composition 
and sequence, size and configuration of peptides. For example, the presence of certain 
amino acids, such as His, Trp, Tyr, Phe, Met, Leu, Gly or Pro has been reported to 
enhance the scavenging activities of peptides (Chen, Muramoto, Yamauchi & Nokihara, 
1996; Park, Jung, Nam, Shahidi & Kim, 2001; Hernández-Ledesma, Dávalos, 
Bartolomé & Amigo, 2005; Mendis, Rajapakse & Kim, 2005b; Li, Chen, Wang, Ji & 
Wu, 2007). Regarding the ACE-inhibitory activity, binding to ACE is strongly 
influenced by the C-terminal tripeptide sequence. Although the structure-activity 
relationship of food derived ACE inhibitory peptides has not yet been fully established, 
ACE prefers inhibitors containing hydrophobic amino acid residues at each of the three 
C-terminal positions (Murray & FitzGerald, 2007). 
The objective of this study was the isolation and identification of peptides sequences 
with antioxidant activity from an enzymatic hydrolysate of squid gelatin. Furthermore, 
the ACE-inhibitory activity of the isolated peptides was evaluated, as well as the 
contribution of Leu and Hyp residues to both biological activities.  
 
2. Materials and methods 
2.1. Gelatin hydrolysate 
Frozen inner and outer tunics of jumbo flying squid (Dosidicus gigas) were kindly 
provided by PSK Océanos, S.A. (Vigo, Spain). Gelatin was extracted using the method 
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described by Giménez et al., 2009. Dry gelatin (2.5% w/v) was dissolved in MiliQ 
water and subjected to enzymatic hydrolysis using Alcalase

 (EC 3.4.21.14, 2.4L, 2.64 
AU/g, Sigma-Aldrich, Inc., St. Louis, Mo., USA) with an enzyme-substrate ratio of 
1:20 (w:w) in optimal conditions for enzymatic activity (pH 8, 50 ºC) for 3 h. The pH of 
the reaction was kept constant by addition of 1N NaOH solution to the reaction medium 
using a pH-stat (TIM 856, Radiometer Analytical, Villeurbanne Cedex, France). The 
enzyme was inactivated by heating at 90 ºC for 10 min and the gelatin hydrolysate was 
the supernatant after centrifugation at 3000 g for 15 min.  
The degree of hydrolysis (DH), calculated according to Adler-Nissen (1977), was 
30.52%. 
 
2.2. Fractionation of the hydrolysate 
Ultrafiltration 
The gelatin hydrolysate was fractionated by ultrafiltration with a molecular weight cut-
off (MWCO) membrane of 10 kDa (Omega 10 kD Centramate
TM
 cassette medium 
screen channel, Pall Corporation, Madrid, Spain). The hydrolysate permeate fraction 
was freeze-dried and designed as UF-10. 
 
Size-exclusion chromatography (SEC) 
The UF-10 was dissolved in MiliQ water at 10 mg/mL and loaded onto a gel filtration 
column (HiLoad
TM
 26/60 Superdex 30 pg, GE Healthcare, Barcelona, Spain), with a 
fractionation range below 10000 Da. The injection volume was 2 mL and the flow rate 
0.5 mL/min using MiliQ water as mobile phase. Peptides monitored at 215 nm were 
collected, freeze-dried and stored at -80 ºC for further assay. Vitamin B12 (1355 Da, 
Sigma Aldrich, Madrid, Spain) and 6.7-dimethoxy-2-(4-methyl-1.4-diazepan-1-yl) 
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quinazolin-4-amine (317 Da, from Lera´s group, University of Vigo, Spain) were used 
as molecular weight standard. 
 
2.3. Amino acid composition 
The different fractions isolated by SEC were dissolved at 1mg/mL in MiliQ water. An 
amount of 50 µL of sample were dried and hydrolysed in vacuum-sealed glass tubes at 
110 ºC for 24 h in the presence of continuously boiling 6 N HCl containing 0.1% phenol 
with norleucine (Sigma-Aldrich, Inc., St. Louis, MO, USA) as internal standard. After 
hydrolysis, samples were again vacuum-dried, dissolved in application buffer, and 
injected onto a Biochrom 20 amino acid analyser (Pharmacia, Barcelona, Spain).  
 
2.4. Antioxidant activities 
FRAP assay 
 
FRAP (Ferric Reducing Ability of Plasma) is a measure of the reducing power of 
samples and was performed according to the method described by Benzie and Strain 
(1996) with some modification. An amount of 60 μL of dissolved sample (UF-10, 
peptide fractions, synthetic peptides) was incubated (37 ºC) with 60 μL of MiliQ water 
and 900 μL of FRAP reagent containing 10 mM of TPTZ (2,4,6-tripyridyl-s-triazine) 
and 20 mM of FeCl3. Absorbance values were read at 595 nm after 30 min. Results 
were expressed as μmol Fe2+ equivalents/g of protein, based on a standard curve of  
FeSO4·7H2O. All determinations were performed at least in triplicate. 
 
ABTS assay 
The ABTS radical 2,2’-azino-bis-(3-ethylbenzothiazoline-6-sulfonic acid)  scavenging 
capacity was carried out according to the method of Re, Pellegrini, Proteggente, 
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Pannala, Yang, and Rice-Evans (1999). The stock solution of ABTS radical consisted of 
7 mM ABTS in potassium persulphate 2.45 mM, kept in the dark at room temperature 
for 16 h. An aliquot of stock solution was diluted with MiliQ water in order to prepare 
the working solution of ABTS radical with absorbance at 734 nm of 0.70 ± 0.02. A 20 
µL aliquot of sample (UF-10, peptide fractions, synthetic peptides) was mixed with 
980 μL of ABTS reagent. The mixture was then left to stand in the dark at 30 ºC for 
10 min and absorbance values were read at 734 nm. Results were expressed as mg 
Vitamin C Equivalent Antioxidant Capacity (VCEAC)/g of protein, based on a standard 
curve of vitamin C. All determinations were performed at least in triplicate. 
 
2.5. Purification of the antioxidative peptides 
The fraction with the highest antioxidant activity was analyzed on-line by LC-ESI-IT-
MS/MS using a LC system model Surveyor (Thermo-Finnigan, San Jose, CA, USA) 
coupled with a linear IT mass spectrometer model LTQ (Thermo-Finnigan). Peptides 
were concentrated onto a RP trap column (PepMap C18 µ-precolumn 300 mm id x 1 
mm; Dionex, Amsterdam, The Netherlands) for 5 min and eluted online onto a 75 μm х 
100 mm Biobasic-C18 RP analytical column (PicoFrit column, New Objective, 
Ringoes, NJ, USA) at a flow rate of 200 nL/min. Water containing 0.1% of  formic acid 
and acetonitrile containing 0.1% of  formic acid, were used as solvents A and B, 
respectively, using the following gradient: 5% B for 5 min, 5-70% B in 60 min, and 
95% B for 10 min. The mass spectrometer was operated in the data-dependent mode to 
automatically switch between full MS and MS/MS acquisition. The parameters for ion 
scanning were the following: Full-scan MS (400-1800 m/z) plus top twelve peaks Zoom 
and MS/MS scans (isolation width 2 m/z), normalized collision energy 35%. The 
scanning was performed using a dynamic exclusion list (20s exclusion list size of 50).  
 8 
De novo peptide sequencing of the major peaks was performed by manual interpretation 
of the ion series in the spectra. BLAST program was used for homology searches 
between manual obtained sequences and those in the NCBInr database. 
 
MALDI-TOF MS Analysis 
The fraction with the highest antioxidant activity was also analyzed by MALDI-TOF 
MS. 1 µL was spotted onto a MALDI target plate and allowed to air-dry at room 
temperature. Then, 0.4 µL of a 3 mg/ml of -cyano-4-hydroxy-transcinnamic acid 
matrix (Sigma) in 50% acetonitrile were added to the dried peptide digest spots and 
allowed again to air-dry at room temperature. MALDI-TOF MS analyses were 
performed in a 4800 Proteomics Analyzer MALDI-TOF/TOF mass spectrometer 
(Applied Biosystems, Framingham, MA) operated in positive reflector mode, with an 
accelerating voltage of 20000 V. 
 
2.6. Peptide syntheses 
Peptides were synthesized by Fmoc solid-phase using an Applied Biosystems Model 
432A Synergy peptide synthesizer. The purity of the peptides was verified by analytical 
mass spectrometer system (Thermo Mod. Finnigan
TM
 LXQ
TM
) coupled to a Surveyor 
HPLC. 
 
2.7. ACE inhibition 
The reversed-phase high performance liquid chromatography (RP-HPLC) was used to 
determine the ACE inhibition capacity of the synthetic peptides. The method was 
according to Wu, Aluko and Muir (2002) with some modifications. The total reaction 
volume was 225 µL, made up of 50 µL of 5 mM HHL, 160 µL of 0.025 U/mL of ACE 
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and 20 µL of sample at different concentration (all prepared with 100 mM potassium-
phosphate buffer, containing 300 mM NaCl, pH 8.3). The mix was incubated at 37 ºC 
during 120 min and the reaction was quenched by addition of 100 µL 0.1 M HCl. The 
released hippuric acid (HA) was quantified by RP-HPLC (model SPE-MA10AVP, 
Shimadzu, Kyoto, Japan) on a C18 column (Tracel excel, 120 ODSA 5 µm, 
Teknokroma, Barcelona, Spain). The injection volume was 50 µL and the flow rate 0.8 
mL/min using an acetonitrile gradient from 20 to 60% in 0.1% trifluoroacetic acid 
(TFA) (v/v) for 26 min. The HHL and HA were monitored at 228 nm and eluted at 8.30 
and 15.70 min respectively. All determinations were carried out at least in triplicate. 
The IC50 value was defined as the concentration of peptide (μM) required to reduce the 
HA peak by 50% (indicating 50% inhibition of ACE activity). All determinations were 
performed at least in triplicate. 
 
3. Results and Discussion 
3.1. Fractionation of the hydrolysate 
The hydrolysate of squid gelatin was ultrafiltered through an ultrafiltration membrane 
with a molecular weight cut-off of 10 kDa to enrich it in low molecular weight peptides, 
which have been associated with antioxidant activity (Gómez-Guillén, López-Caballero, 
Alemán, López de Lacey, Giménez and Montero, 2010). 
The ultrafiltrate (UF-10) was then fractionated by size exclusion chromatography and 
four fractions were collected based on the chromatogram, named I, II, III and IV, 
respectively (Figure 1). Both the amino acid composition and antioxidant activity of the 
separated fractions were evaluated.  
 
Antioxidant activity and amino acid composition of fractions 
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The antioxidant activity of both UF-10 and peptide fractions was evaluated by FRAP 
and ABTS (Figure 2). Reducing power is a measure of global antioxidant capacity as 
antioxidants show reducing power in redox reactions (Cumby, Zhong, Naczk & 
Shahidi, 2008). Although all the peptide fractions showed a ferric reducing ability 
significantly higher than that of UF-10 (Fig. 2A), FRAP values were noticeably higher 
in fractions FI, FII and FIII. The highest reducing power was found in fraction FIII, 
with a 6-fold increase compared to UF-10.  
Regarding ABTS radical scavenging ability, all the fractions showed significantly lower 
VCEAC values than UF-10 (Fig. 2B). Among the peptide fractions, FIII showed the 
highest radical scavenging ability, followed by fractions FII, FI and FIV. An increase of 
FRAP and ABTS values with decreasing the molecular weight from fractions I to III 
was found in this study. However, fraction FIV, with the lowest molecular weight, 
showed the lowest antioxidant activity measured by both ABTS and FRAP, probably 
due to the presence of large number of free amino acid and small peptides without 
antioxidant capacity. Wu, Chen, and Shiau, (2003) and Je, Park, and Kim, (2005) 
fractioned by molecular mass a protein hydrolysate from mackerel and hoki frame 
respectively and also found the lowest antioxidant activity on the fraction with lowest 
molecular weight. 
The fractions collected were subjected to amino acid composition analysis (Table 1) in 
order to determine the possible effect of the amino acid profile on the antioxidant 
activity. Although the major constituent amino acids of all the fractions were Gly, Glu, 
Ala, Pro and Hyp, some differences were remarkable. Thus, Asp content in FI and II 
was 2-fold higher than in FIII and FIV. Glu content was noticeably higher in FIII, 
whereas FIV showed the highest contents of Ala, Leu, Phe or Pro. Based only on the 
content of these amino acids in the four fractions, one could expect slight differences in 
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the antioxidant activity of these fractions. However, as described above, FIII clearly 
showed the highest antioxidant activity measured by both FRAP and ABTS. In 
agreement with other studies, besides the amino acid profile and the molecular weight, 
the amino acid sequence of the peptides may greatly contribute to generate the 
antioxidant activity observed (Suetsuna, Ukeda, & Ochi, 2000; Ren et al., 2008). 
 
3.2. Identification of compounds by LC-MS/MS 
Fraction FIII was collected and subjected to LC-ESI-IT-MS/MS to identify putative 
antioxidant peptides. Two major peaks were observed in the LC chromatogram (Figure 
3A). Figure 3B shows the MS spectrum of the peak 1, where the ion of m/z 952.42 was 
the most abundant. The collision induced fragmentation of this compound is shown in 
Figure 3C. A major ion of m/z 702.32 and several fragments that differed in units of 
m/z 146 were observed in the mass spectrum, which would correspond to the loss of a 
unit of dehydrofucose. According to König and Leary (1998), this finding largely 
suggested that the compound with m/z 952.42 could be mostly comprised by the 
carbohydrate fucose. Other minor components present also in the m/z 952 ion could be 
carbohydrate units or amino acids. Collagen structure has been shown to content 
carbohydrate units covalently joined to amino acid residues (Wells-Knecht, Lyons, 
McCance, Thorpe, Feather, & Baynes, 1994; Knott & Bailey, 1998; Paschalis, Verdelis, 
Doty, Boskey, Mendelsohn, & Yamauchi, 2001; Muyonga, Cole & Duodu, 2004). The 
carbohydrate units more frequently found in collagen are glucose and galactose, as well 
as mannose, fucose, sialic acid or hexosamines in small amounts (Spiro, 1969; de Paz-
Lugo, 2006). In previous studies, a significantly higher carbohydrate content has been 
reported in squid gelatin when compared to gelatin extracted from other marine species 
(Giménez et al., 2009), and we hypothesize that the presence of glycosylated peptides 
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may play an important role in the higher antioxidant activity observed in squid gelatin 
(Giménez et al., 2009). In connection with this, glycoproteins have been reported to be 
able to scavenge free radicals such as 1,1-Diphenyl-2-picrylhydrazyl radical (DPPH) or 
oxygen radicals as a consequence of the high polarity in the carbohydrate part of the 
whole glycoprotein molecule (Oh & Lim, 2008). 
Figure 4A shows the MS spectrum of the second most abundant component from the 
fraction FIII (peak 2 in Figure 3A), which contained a major ion at m/z 1410.63 Da. De 
novo sequencing of this compound with m/z 1410.63 Da was performed by manual 
interpretation of the ion series in the fragmentation spectrum (Figure 4B) and the 
sequence was determined to be Gly-Pro-X-Gly-X-X-Gly-Phe-X-Gly-Pro-X-Gly-X-Ser, 
with the positions marked as X occupied by either Hyp or Leu, since the MS/MS 
analysis performed could not differentiate between the molecular weight of Hyp (131.17 
Da) and Leu (131.13 Da). In view of this result, FIII was subjected to MALDI-TOF MS 
analysis. However, no peak masses were detected (data not shown). 
As it was not feasible to distinguish between Hyp and Leu, tentatively three peptide 
structures were proposed: (I) Leu in all the positions marked as X (Gly-Pro-Leu-Gly-
Leu-Leu-Gly-Phe-Leu-Gly-Pro-Leu-Gly-Leu-Ser), (II) Hyp in all the positions marked 
as X (Gly-Pro-Hyp-Gly-Hyp-Hyp-Gly-Phe-Hyp-Gly-Pro-Hyp-Gly-Hyp-Ser) and (III) 
Leu only in the fourth X position (Gly-Pro-Hyp-Gly-Hyp-Hyp-Gly-Phe-Leu-Gly-Pro-
Hyp-Gly-Hyp-Ser). This third structure was proposed based on homology between the 
sequence and those described as collagen in the NCBInr database, as well as on the 
amino acid composition of the fraction FIII. As the content of Hyp was over 3-fold 
higher than that of Leu in this peptide fraction (Table 1), one residue of Leu could be 
expected every 6 residues of Hyp. Furthermore, Pro and Hyp frequently follow each 
other and the Gly-Pro-Hyp sequences make up about 10% of the collagen molecule 
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(Nimni & Harkness, 1988). As it can be observed, these sequences have Gly every three 
amino acids, typical from collagen molecule where glycine represents 33-34% of the 
amino acid residues. 
The three proposed peptides were further synthesized to test the antioxidant activity by 
both ferric reducing ability (FRAP) and ABTS radical scavenging capacity. 
 
3.3. Antioxidant activity of synthetically derived peptides 
Ferric reducing power and ABTS radical scavenging ability of the proposed peptides are 
shown in Figure 5. Peptide I (with Leu in all the positions marked as X) showed both 
the highest FRAP (Figure 5A) and ABTS values (Figure 5B). Total or partial 
replacement of Leu by Hyp residues to obtain peptides II and III, respectively, gave rise 
to a 2-fold decrease both in reducing power and radical scavenging ability. Therefore, 
the presence of Leu residues in these sequences seems to play an important role in the 
antioxidant activity of the peptides. Dávalos, Miguel, Bartolomé and López-Fandiño 
(2004) working on the activity of individual amino acids reported that, Trp, Tyr, Met 
showed the highest antioxidant activity, followed by Cys, His and Phe. The rest of the 
amino acids did not show any antioxidant activity. However, many peptides have been 
described to have antioxidant capacity without containing any of the above mentioned 
proton-donating amino acid residues in their sequences. Thus, Rajapkase et al. (2005) 
reported two antioxidant peptides, Asn-Gly-Leu-Glu-Gly-Leu-Lys and Asn-Ala-Asp-
Phe-Gly-Leu-Asn-Gly-Leu-Glu-Gly-Leu-Ala isolated from giant squid muscle protein. 
Li, Chen, Wang, Ji, and Wu (2007) identified the peptide Gln-Gly-Ala-Arg, which 
exhibited the highest antioxidant activity from porcine skin collagen hydrolysates. 
Therefore, the amino acid sequence of the peptide might play an important role in its 
activity (Ren et al., 2008; Suetsuna et al., 2000). Leu has been reported to enhance the 
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scavenging activities of peptides (Park et al., 2001; Li et al., 2007), as it has been also 
shown in this study. Furthermore, Gly and Pro have been suggested to play an important 
role in radical scavenging ability of some peptides (Mendis et al., 2005b; Chen et al., 
1996; Rajapakse et al., 2005). The side-chain of Gly consists of a single hydrogen atom 
and may confer high flexibility on the peptide backbone. Moreover, the pyrrolidine ring 
of Pro tends to interrupt the secondary structure of the peptide imposing conformational 
constraints. As a consequence, the presence of these amino acids may increase the 
availability of the amino acid residues of the peptide sequences to act as antioxidants. 
Peptide I had the most hydrophobic sequence. With the exception of Ser, all the amino 
acid residues were hydrophobic (Leu, Pro, Phe), with leucine composing approximately 
40% of the peptide sequence. Since hydrophobicity of antioxidants is important for 
accessibility to hydrophobic targets (Chen et al., 1996), it may be presumed that the 
presence of leucine in the peptide sequence may contribute to lipid oxidation inhibition 
by increasing solubility of peptides in lipid. 
When the antioxidant capacity of the synthetic peptides was compared to that described 
for the fraction FIII, only the peptide I showed FRAP values similar to those found in F 
III (38.2 mol FeEq/g on average), whereas ferric reducing power of peptides II and III 
was about 2-fold lower. Regarding ABTS, synthetic peptides showed between 3- and 4-
fold lower ABTS values than those described for FIII. Therefore, these sequences, in 
spite of corresponding to one of the most abundant compounds found in fraction FIII 
and the high content of Leu residues in the sequence of peptide I, were not directly 
responsible for the radical scavenging capacity observed in this fraction. The ABTS 
radical scavenging capacity observed in FIII may be attributed to other peptidic 
sequences with antiradical capacity although present in smaller quantities, together with 
the likely presence of glycosylated peptides. Other peptides isolated from skin gelatin 
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hydrolysates of marine species have demonstrated noticeable free-radical scavenging 
activity (Mendis et al., 2005ab; Li et al., 2007). 
 
3.4. ACE inhibitory activity of synthetically derived peptides 
The fractions III and IV also presented ACE inhibitory capacity, although it was low 
and it was not possible to determine the IC50 values (amount of sample required to 
inhibit 50% of the ACE activity). However, the capacity to inhibit the ACE was found 
to be very high in the synthesized peptides. The IC50 of the peptides is shown in table 2. 
The molecular weight of these peptides was approximately of 1400 Da, which is on the 
average molecular weight proposed by Zeng, Li, Chen, Li and Wu (2005) for ACE 
inhibitory peptides from aquatic products, mostly below 1500 Da. The ACE inhibitory 
capacity was highly dependent on the peptide sequence. Peptide I showed the most 
potent effect (IC50 90.03 μM), followed by peptide III (IC50 256.82 μM). However, 
peptide II did not show any ACE inhibitory activity. Although the structure-activity 
relationship of food derived ACE inhibitory peptides has not yet been fully established, 
correlation among different peptide inhibitors of ACE indicate that binding to this 
enzyme is strongly influenced by the C-terminal tripeptide sequence of the substrate or 
inhibitor. ACE appears to prefer substrates or competitive inhibitors that mainly have 
hydrophobic (aromatic or branched side chains) amino acid residues at the three C-
terminal positions (Murray & FitzGerald, 2007). Therefore, the presence of Leu and Gly 
in peptide I at the second and third positions from carboxyl-terminus seems to play an 
important role in the ACE inhibitory activity. Although peptides II and III shared the 
same tripeptide sequence at the carboxyl terminus, peptide II was inactive as ACE 
inhibitor (Table 2). Wu, Aluko and Nakai (2006) reported that in case of long-chain 
peptides (more than five residues), as in this case, the C-terminal tetrapeptide residues 
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were more important to their ACE-inhibitory activity than the C-terminal tripeptide 
sequence. However, this finding does not either explain the difference between peptides 
II and III, since they also have the same C-terminal tetrapeptide sequence. Moreover, 
several authors have suggested that in case of long peptides, it is expected that peptide 
conformation, i.e. the structure adopted in the specific environment of the binding site 
will influence binding to ACE, and therefore the ACE inhibitory capacity of these 
peptides (FitzGerald & Meisel, 2000; Meisel, 2003; Meisel, Walsh, Murray & 
FitzGerald, 2005). Peptides II and III differs in the seventh position from the carboxyl 
terminus (Hyp in peptide II; Leu in peptide III). The different polarity of these two 
residues may involve conformational changes in the peptide backbone that influence the 
ACE inhibitory capacity. 
The antihypertensive effects of collagen hydrolysates prepared from various sources and 
the isolation of several ACE inhibitory peptides from those hydrolysates have been 
reported in previous works (Byun & Kim, 2001; Fahmi et al., 2004; Zhao et al., 2007; 
Saiga et al., 2008; Ichimura, Yamanaka, Otsuka, Yamashita & Maruyama, 2009). 
However, the use of different methods and their associated modifications to test ACE 
inhibitory capacity makes difficult the direct comparison of IC50 values from different 
studies when some reports do not detail the number of enzyme units used in the 
inhibition analysis or do not include an IC50 value for an ACE inhibitory standard such 
as Captopril® (Murray, Walsh & FitzGerald, 2004). As an example, the dipeptide Ala-
Pro has been reported with IC50 values ranging from 29 to 230 M (Wyvratt & Patchett, 
1985; Ichimura, Hu, Aita & Maruyama, 2003; Fuglsang, Nilsson & Nyborg, 2003). 
Another example is Ala-Val-Pro-Tyr-Pro-Gln-Arg, obtained from -casein f (177-183), 
with reported IC50 values ranging from 15 to 274 M (Nurminen, 1999; Pihlanto-
Leppälä, Rokka & Korhonen, 1998). In connection with this, Wu et al. (2002) have 
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reported that the spectrophotometric assay described by Cushman and Cheung (1971), 
widely used for testing ACE inhibition of gelatin hydrolysates, tends to overestimate the 
amount of HA produced during ACE-catalyzed reactions. Having this in mind, IC50 
values of the most potent inhibitor (peptide I), were between 26- and 1.5-fold higher 
than those reported for ACE inhibitory peptides derived from different food proteins, 
tested in similar conditions (Centeno et al., 2006; He, Chen, Sun, Zhang & Zhou, 2006; 
Tsai, Lin, Chen, & Pan, 2006; Tauzin, Miclo, & Gaillard, 2002). Therefore, peptide I 
could be considered as a moderate ACE inhibitory peptide. Nevertheless, these IC50 
values are still far from the IC50 value obtained for the synthetic ACE inhibitor enalapril 
in this study (7.34 M, Table 2) or that reported for captopril (0.022 M) (WHO, 2003). 
However, it is known that these drugs can cause adverse side effects (Messerli, 1999; 
Tabacova & Kimmel, 2001). Furthermore, some ACE inhibitors have been reported to 
have better in vivo properties than the efficacy levels extrapolated from in vitro effects 
(Vermeirssen, van Camp & Verstraete, 2004), probably due to the higher affinity of 
these peptides for tissue and slower elimination of them than of a drug compound. It 
should be pointed out that the sequence Gly-Phe-Hyp-Gly-Pro that takes part of the 
inactive ACE inhibitory peptide II, has been reported to significantly decrease the blood 
pressure of the spontaneously hypertensive rats (SHRs) with long-term efficiency when 
orally administered at both 30 and 10 mg/kg (Ichimura et al., 2009). Furthermore, the 
dipeptide Gly-Pro, that exists in collagen as a large number of repeated sequences and is 
contained in all the proposed peptides (I, II and III), also showed antihypertensive effect 
in SHRs (Ichimura et al., 2009). These findings suggest that the antihypertensive effect 
of peptides I, II and III might improve after oral administration due to the release of 
more active sequences by gastrointestinal digestion. 
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4. Conclusions 
A squid gelatin hydrolysate was separated by ultrafiltration and size-exclusion 
chromatography and all the peptide fractions showed a ferric reducing power 
significantly higher than the hydrolysate. In contrast, the ABTS radical scavenging was 
higher in the gelatin hydrolysate than in the different fractions. The presence of Leu 
residues in the peptide sequence (Gly-Pro-Leu-Gly-Leu-Leu-Gly-Phe-Leu-Gly-Pro-
Leu-Gly-Leu-Ser), seem to play an important role in their antioxidant and ACE-
inhibitory activity. Furthermost, the presence of glycosylated peptides may contribute to 
the high antioxidant activity of the squid gelatin hydrolysate. 
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Legends to Figures 
Figure 1. Size-exclusion chromatogram of UF-10. 
Figure 2. Ferric reducing power (FRAP) (2A) and ABTS radical scavenging capacity 
(2B) of UF-10 and the fractions FI, FII, FIII and FIV separated by size exclusion 
chromatography. 
Figure 3. LC chromatogram of fraction FIII (3A), MS spectrum of the peak 1 (3B) and 
MS/MS spectrum of the compound with m/z 952.42 (3C). 
Figure 4. MS spectrum of the peak 2 present in the LC chromatogram of fraction FIII 
(4A) and MS/MS spectrum of the compound with m/z 1410.63 (4B). 
Figure 5. Ferric reducing power (FRAP) (5A) and ABTS radical scavenging capacity 
(5B) of the synthetic peptides. 
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Table 1. Comparative amino acid profiles of fractionated UF-10 
 Number of residues/1000 residues 
Amino acid F I F II F III F IV 
Asp 99 128 39 43 
Thr 35 34 27 39 
Ser 49 58 45 66 
Glu 154 109 218 78 
Gly 317 293 346 307 
Ala 96 104 77 150 
Cys 6 8 10 0 
Val 21 19 22 29 
Met 16 26 6 14 
Ile 14 17 15 11 
Leu 23 24 26 46 
Tyr 3 5 8 10 
Phe 10 11 9 18 
His 1 1 0 0 
Lys 1 2 3 1 
Arg 5 4 6 7 
Pro 70 76 59 93 
Hyp 74 75 82 87 
Hyl 5 8 1 0 
Table(s) 1
Table 2. ACE inhibitory capacity of synthetic peptides and Enalapril 
 
 
 
 IC50 M 
Peptide I 90.03 
Peptide II non-detected 
Peptide III 256.82 
Enalapril 7.34 
 
Table(s) 2
